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Background: Plantar ulcers, which commonly occur in leprosy patients, tend to recur increasing physical disability.
The aim of this study is to identify both the bacteriological profile of these ulcers and the antibiotic susceptibility of
the isolated bacteria.
Materials and methods: 68 leprosy patients with chronic ulcers attending the in-patient department of Gambo
General Hospital, West Arsi, were included in this study. Proper sample collection, inoculation on culture media, and
final identification using biochemical methods were undertaken.
Results: 66 patients (97.1%) had a positive culture. A total of 81 microorganisms were isolated. Multiple organisms
(two or more) were isolated in 15 (22.7% out of positive culture) patients. The main isolation was Proteus spp
(30.9%), followed by Escherichia coli (21.0%), Staphylococcus aureus (18.5%) and Pseudomonas aeruginosa (9.9%). In
the total number of the isolated bacteria, the antibiotics with less resistance were gentamicin (18.5%), fosfomycin
(22.2%) cefoxitin (24.7%), ceftriaxone (25.9%) ciprofloxacin (25.9%), and amoxicillin-clavulanic acid (28.49%).
Conclusion: The bacteriological study of plantar ulcers of leprosy patients revealed Enterobacteriaceae and S.
aureus as the main pathogens involved in such infections. The results of this study may guide empirical therapy in
a rural area hospital where culture and susceptibility testing facilities are scarce.
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Leprosy is a chronic infectious disease caused by the obli-
gate intracellular pathogen Mycobacterium leprae [1], and
still remains a public health problem, mainly in Africa,
Asia and Latin America [2]. It has many complications in-
cluding: leprosy reactions, development of plantar and
palmar ulcerations, lagophthalmos (loss of eyelid function)
and corneal anesthesia [3]. Chronic ulcers are included
among the most serious complications of leprosy; these
are highly infected with bacteria, which delays the healing
process [4], and furthermore, they usually recur, which in
such cases increase the physical disability [4]. There is* Correspondence: jramosrincon@yahoo.es
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unless otherwise stated.little information about the pattern of bacterial isolates
and drug sensitivities of infected ulcers in leprosy patients
with leprosy, and most studies have been carried out in
India [4-9]. Some studies have been performed in Africa
[10,11], but to our knowledge only three have been made
in Ethiopia [12-14]. Two of these studies were carried out
in 1970 and 1989, and the third in 2006; they assessed the
bacteriology of infected ulcers and the sensitivity of these
organisms to available antimicrobials in leprosy patients
who visited the ALERT hospital, and the ALERT Hospital,
Kuyera Hospital and Gambo General Hospital (GGH)
[12-14]. In Ethiopia there are four main hospitals provi-
ding special care for leprosy patients: ALERT Hospital,
Kuyera Hospital, Bisidimo Hospital and GGH. GGH is a
rural center with some laboratory facilities, but it is not
provided with any procedure for the isolation and identifi-
cation of bacteria and drug sensitivities.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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which aims was to identify the isolates from infected ul-
cers and drug sensitivities of microorganism isolation
over a period of 4 months.
Material and methods
Setting
GGH is a rural hospital in Ethiopia, which is a referral
institution in the leprosy care program in the country
according to the guidelines of the Tuberculosis and Lep-
rosy Prevention and Control Programme (TLPCP) of the
Ministry of Health of Ethiopia. The GGH is located in
the West-Arsi zone, 250 km south of Addis Ababa.
Type of study
A descriptive cross-sectional prospective study from July
2013 to December 2013.
Case selection
Patients admitted to GGH with ulcers that were chronic,
indolent, with scanty discharge and a pale, unhealthy fi-
brosis base were included. Diagnosis of osteomyelitis
was based on the clinical assessment and physical exam
along with radiographic examinations.
Sample collection
Samples were taken from pus produced by either the
ulcer or from the depth of the ulcer with a sterile bac-
teriological loop.
Identification
Swabs were processed for gram stain and culture. For
isolation of the aerobes, inoculation was done on nutri-
ent agar, blood agar, MacConkey’s agar and Mannitol
agar media and incubated overnight at 37°C, and also
Sabouraud agar at room temperature. Identification
of the isolates was performed using biochemical
methods [15] in cases where there was some doubt
about identification. The microorganisms were identi-
fied by Matrix-Assisted Laser Desorption/Ionization
Time-Of-Flight (MALDI-TOF) in Spain [16,17]. The
isolates were further tested for antibiotic sensitivity to
different classes of antimicrobials on Mueller Hinton
agar medium, using Kirby-Bauer disc diffusion method and
following the guidelines of the Clinical and Laboratory
Standards Institute [18]: (1) Cephalosporin class (cefoxitin,
ceftriaxone); (2) Aminoglycosides class (gentamycin);
(3) Fluorquinolones class (ciprofloxacin); (4) Tetracycline
class (tetracycline, doxycycline); (5) Folate Pathway Inhibitors
(co-trimoxazole o trimethoprim/sulfamethoxazole); (6)
Phenicols class (chloramphenicol); (7) Penicillin class
(oxacillin, ampicillin, amoxicillin, amoxicillin clavulanic
acid, penicillin); (8) Glycopeptides class (vancomycin);
(9) Macrolides class (erythromycin); (10) Lincosamidesclass (clindamycin); (11) Fosfomycin class (fosfomycin);
(12) and Rifampicin class (rifampicin). The microorgan-
isms cefoxitin resistant were also considered as resistant
to methicillin.
Data analysis
Data were analyzed for descriptive statistics using SPSS
version 21 and Microsoft Excel and presented in tables.
The results were interpreted in terms of frequencies and
percentages.
Ethical considerations
Ethics committee approvals were obtained from both
the local Research and Publication Committee of the
GGH and the Health Unit and Ethical Review Commit-
tee of the Ethiopian Catholic Secretary. We ensured that
the study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki as reflected in the
approval by the institution’s human research review
committee. We also made sure that either oral or writ-
ten informed consent was obtained from each patient.
Results and discussion
Forty-four (64.7%) of the 68 patients were male and
twenty four (35.3%) were female. The average age of the
patients was 43.9 (range age: 18 to 75 years old), and the
majority of the patients (n = 38; 55.8%) were aged be-
tween 30–50 years old. Clinical data of leprosy patients
with ulcers are shown in Table 1. Main localization was
the feet (86.8%) (Table 1).
Two (2.9%) out of the 68 cultures performed were
negative and 66 were positive. Eighty-one microorgan-
isms were isolated from infected ulcers as shown in
Table 2. The main isolation was Proteus spp (30.9%),
followed by Escherichia coli (21.0%), Staphylococcus aur-
eus(18.5%) and Pseudomonas aeruginosa (9.9%). Gram-
positive and Gram-negative bacteria accounted for
24.6% and% 70.5% respectively. Funghal microorganism
accounted for 4.9%. Multiple organisms (at least two)
were isolated from 15 (22.7% of positive culture) pa-
tients. The pattern of mixed growth is shown in Table 2:
13.3% of isolation of Candida sp., 26.7% of P. aerugi-
nosa, 33.3% of S. aureus, 26.7% of Proteus spp. and
20.0% of E. coli. The isolation of a specific bacteria did
not have any association with the development of
osteomyelitis.
Susceptibility patterns of Gram-positive and Gram-
negative bacteria isolated from leprosy ulcers against anti-
microbial agents are shown in Table 3. Three isolates of S.
aureus were methicillin resistant (20%), as they were to
cefoxitin. This isolation was sensitive to ciprofloxacin, co-
trimoxazole, vancomicyn, and rifampicin. About 20 to
30% of all S. aureus isolated were resistant to amoxicillin/






Years of leprosy diagnosis
≤ 1 year 7 10.3
> 1 year to 6 year 15 22.1
> 6 year 46 67.6
Time with ulcer
< 1 year 53 77.9




Upper extremities 3 4.4




Finger and sole 2 2.9




White blood cell [x 106//l] [n = 58]
< 4.000 4 6.9
4.000 – 11.000 40 69.0
> 11,0 14 24.1
Hemoglobin [g/dl] [n = 55]
< 12 14 25.5
> 12 41 74.5
SD: standard deviation.
Table 2 Bacteriological isolates of leprosy ulcers among
patients
Pathogens Number Percentages
Gram-positive pathogens 20 24.6
Staphylococcus aureus 15 18.5
Methicillin resistant S. aureus 3 3.7
Coagulase negative Staphylococci 2 2.5
Enterococcus faecalis 1 1.2
Streptococcus agalactiae 1 1.2
Streptococcus pyogenes 1 1.2
Gram-negative pathogens 57 70.5
Enterobacteriaceae 49 60.6
Proteus spp. 25 30.9
Proteus mirabilis 21 25.9
Proteus vulgaris 4 4.9
Escherichia coli 17 21.0
Enterobacter cloacae 2 2.5
Klebsiella pneumoniae 2 2.5
Morganella morganii 2 2.5
Providencia rettgeri 1 1.2
Gram-negative non fermantive
Pseudomonas aeruginosa 8 9.9
Fungal pathogens 4 4.9
Candida spp 4 4.9
Candida albicans 1 1.2
Candida no albicans 3 3.7
Total 81 100
Mixed growth 15* 22.7
Pattern
Staphylococcus aureus and Proteus spp 3 ** 20.0
Staphylococcus aureus and Escherichia coli 2 13.3
Proteus spp and Pseudomonas aeruginosa 2 13.3
Proteus spp and Escherichia coli 2 13.3
Staphylococcus aureus and Pseudomonas
aeruginosa
1 6.7
Proteus spp and Candida sp 1 6.7
Pseudomonas aeruginosa and Candida sp 1 6.7
Staphylococcus aureus and Enterobacter cloacae 1 6.7
Streptococcus agalactiae and Enterobacter
cloacae
1 6.7
Pseudomonas aeruginosa and Escherichia coli 1 6.7
S. aureus and Providencia rettgeri 1 6.7
* Percentage of 66 patients with positive results of culture of ulcer.
** Percentage of 15 patients with mixed growth culture.
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col, ciprofloxacin, co-trimoxazole and clindamycin.
More than 50% of Enterobacteriaceae were resistant to
tetracycline (73.5%), ampicillin (73.5%), amoxicillin
(61.2%) and co-trimoxazole (57.1%); from 40 to 50%
were resistant to erythromycin (51.0%) and chloram-
phenicol (40.8%); from 20 to 40% were resistant to,
doxycycline (32.7%), ciprofloxacin (28.6%), gentamycin
(24.5%), fosfomicyn (22.4%), amoxicillin clavulanic acid
(22.4%) and cefoxitin (18.4%) ; finally, less than 20%
were resistant to ceftriaxone (14.3%). From P. aeruginosa
isolated 50% were resistant to chloramphenicol, 37.5% to
ciprofloxacin and 25% to gentamycin.In the total amount of the isolated bacteria, the anti-
biotics with less resistance were gentamicin (18.5%),
fosfomycin (22.2%), cefoxitin (24.7%), ceftriaxone (25.9%),
Table 3 Antimicrobial drugs resistance pattern of bacteria isolated from leprosy ulcers
Drugs no [%] resistance to
Bacteria AMP AMX AMC CRO FOX FOS GM E C TE CIP SXT DO CC VA RI P OX
S. aureus [n = 15] 12 [80] 15 [100] 4 [26.7] 6 [40] 3 [20.0] 3 [20.0] 0 [0] 4 [26.7] 3 [20.0] 2 [13.3] 3 [20.0] 4 [26.7] 0 3 [20] 0 0 12 [80] 3 [20]
Streptococcus spp [n = 2] - - - - - - - 1 [50.0] - - - 1 [50.0] - - - - 0 -
E. faecalis[n = 1] 0 [0] 0 [0] 0 [0] 1 [100] 1 [100] 0 [0] 1 [100] 1 [100] 0 [0] - - 0 0 0 1 [100]
Proteus spp.[n = 25] 17 [68.0] 13 [52.0] 5 [20.0] 2 [8.0] 3 [12.0] 4 [16.0] 8 [32.0] 12 [48.0] 9 [36.0] 24 [96.0] 8 [32.0] 14 [56.0] 7 [28.0]
E. coli [n = 17] 12 [70.6] 11 [64.7] 1 [5.9] 1 [5.9] 2 [11.8] 3 [17.6] 2 [11.8] 7 [41.2] 6 [35.3] 7 [41.2] 5 [29.4] 10 [58.8] 5 [29.4]
Others* [n = 7] 7 [100] 6 [85.7] 5 [71.4] 4 [57.1] 5 [71.4] 4 [57.1] 2 [28.6] 6 [85.7] 5 [71.4] 5 [71.4] 1 [14.3] 4 [57.1] 4 [57.1]
Total Enterobacteriaceas
[n = 49]
36 [73.5] 30 [61.2] 11 [22.4] 7 [14.3] 10 [20.44] 11 [22.4] 12 [24.5] 25 [51.0] 20 [40.8] 36 [73.5] 14 [28.6] 28 [57.1] 16 [32.7]
P. aeruginosa[n = 8] 8 [100] 8 [100] 8 [100] 7 [87.5] 6 [75.0] 4 [50.0] 2 [25.0] 8 [100] 4 [50.0] 8 [100] 3 [37.5] 8 [100] 8 [100]
Key: OX = Oxacillin, FOX = Cefoxitin, AMC: Amoxicillin clavulanic acid, E = Erythromycin, CC = Clindamycin, AMP = Ampicillin, AMX; Amoxicilin; P = Penicillin, TE = Tetracycline, DO = Doxycycline, CRO = Ceftriaxone,
SXT = Co-trimoxazole, GN = Gentamycin, VA = Vancomycin, CIP = Ciprofloxacin, C = Chloramphenicol, RI: Rifampicin, FOS: Fosfomicyn. *Klebsiella pneumoniae [n = 2], Enterobacter cloacae [n = 2], Morganella morganiii
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acid (28.4%), doxycycline (29.6%), chloramphenicol (33.3%),
erythromycin (46.9%), co-trimoxazole (50.6%) and tetracyc-
line (56.8%). Most of the bacteria were resistant to both
amoxicillin (65.4%) and ampicillin (69.1%).
Among the various complications that occur in leprosy
are plantar, palmar and corneal ulcerations [14,19] and
once these ulcers develop, secondary bacterial infections
usually follow. Bacterial etiologies of these infections
have not been studied in depth and published informa-
tion is scarce in Ethiopia [12-14].
Diversified bacteriological agents have been identified
in different studies, and in ours the main pathogens
were Enterobacteriaceae, followed by S. aureus and P.
aeruginosa, being Proteus mirabilis the most common
pathogen isolated. In a study of Indian leprosy patients
with ulcers, by Kumar et al., the most common isolate
was P. aeruginosa [6], which is similar to studies re-
ported elsewhere [14]. However, the results in most of
the studies are around 10% for P. aeruginosa [10,14,20],
with S. aureus being the major isolate in studies carried
out in India, South Africa and Mali [9-11,20,21]. In this
paper, S. aureus was the second bacteria isolate with a
prevalence of 18.5%, which is the most virulent of all
Staphylococci encountered. The invasive nature of this
organism poses a threat for deeper tissue invasion and a
potential risk for bacteremia.
Antimicrobial resistance is increasing, which is a
worldwide problem that continues to challenge medical
practice [22,23], and has become an important concern
for the clinician, patients and the pharmaceutical indus-
tries in both the hospital and community environment
[23]. 20% of cases were resistant to methicillin, higher
prevalence than it has been found in others studies
about leprosy ulcers (9%) [14]. Maybe it is related to the
empirical treatment with cloxacillin previous to this
study. Methicillin resistant S. aureus(MRSA) is a rele-
vant problem because of the impossibility to treat with
methicillin or oxacillin, representing a deeper dilemma
in developing countries. Enterobacteriaceae is more than
50% resistant to co-trimoxazole and 20% resistant to cip-
rofloxacin. The best antimicrobial choice for treating this
bacterium is ceftriaxone followed by amoxicillin clavula-
nic acid and fosfomycin, because it is less prevalent to
be resistant. The isolation of P. aeruginosa is a problem,
because no appropriate antibiotics, such as ceftazidime
or carbapenem, are available in rural areas of low-
income countries.
When should antibiotics be used to manage leprosy ul-
cers? According to Lema et al. [14] the use of antibiotics
has two main rules: the first rule is ‘do not use antibiotics
as a routine’; the second general rule is ‘do not fail to use
appropriate antibiotics when needed’. Ulcers with osteo-
myelitis, however, need antibiotics to recover the affectedarea from microorganisms and to cure osteomyelitis. Anti-
biotic treatment is then empirical because cultures of in-
fected ulcers and the sensitivity of the microorganisms are
not available in rural areas. After this pilot study in our hos-
pital, we can empirically choose a better antibiotic when it
is not possible to perform cultures. According to the results
of our study, aminoglycosides (gentamicin), quinolones
(ciprofloxacin), fosfomycin, amoxicillin-clavulanic acid and
cephalosporin of second and third generation (ceftriaxone,
cefoxitin), suggested as treatment options, show less than
30% resistance.
Moreover, it should be noted the fact that daily ulcer
care and shoe adjustments are as important as oral anti-
biotics in these cases. Several investigators have been
working with alternative therapeutic options for the
management of lepromatous ulcers by using topical
agents such as citric acid [22,24] or phenytoin sodium
with Zinc oxide [20,25], when ulcers do not heal. Pre-
ventive surgery could accelerate the healing of this kind
of ulcer. Other conservative approaches, such as ortho-
pedic interventions involve reduction of bone hyper
pressure areas, which then enables ulcer healing [26].
Moreover, various loco-regional flaps have been de-
scribed for the reconstruction of trophic ulcers, but very
large defects, on the other hand, are not amenable to
local flaps [27]. Other authors used a free tissue transfer
form (a radial artery forearm free flap), one of the op-
tions for trophic ulcer complicating leprosy [28].
In a systematic review of the literature about the qual-
ity of reporting andmethodology of studies on interven-
tions for trophic ulcers in leprosy, Forsetlund and Reinar
[29] concluded that the existing infrastructure in the lep-
rosy field, and the presumably restricted funds for treat-
ment and research, may limit the opportunities for
undertaking high quality randomized controlled trials.
Moreover, the most important threat in existing studies
is the threat of selection bias; for instance, there is an
apparent need to stimulate more research and improve
methodological quality, as well as the quality of report-
ing the trials in leprosy ulcer treatment [30].
In this study the osteomyelitis presented in 45% of the
patients, which was higher than in other studies [8,9,13].
This might be due to the fact that GGH is a reference
hospital, where the patients come for ulcer treatment ,
and there is a team of orthopaedic surgery operating this
kind of pathology four times a year. Besides that, some
microorganisms such as S. aureus have a higher risk to
cause osteomyelitis, but in our study the isolation of a
specific bacteria did not have any association with
osteomyelitis.
This pilot study has some limitations because cultures
for anaerobic bacteria could not be performed, nor have
we followed the patients up undergoing antibiotic treat-
ment to see the outcome of their ulcers.
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life of leprosy patients [14,19,21,25]. The situation with
regards to leprosy is pathetic, and hampers the restor-
ation of social status to leprosy patients, which in turn
contributes to a greater misunderstanding about the dis-
ease spreading [21,25]. Bacteriological study of the ulcers
of leprosy patients is appropriate to identify the patho-
gens and sensitivity. The pathogens in this study are dif-
ferent to those causing disease in others countries, being
Proteus spp the main pathogen involved. For this reason,
it is believed that an effort should be made in order to
improve the management of chronic ulcers of leprosy
patients. This could begin performing bacterial cultures
to guide an appropriate antibiotic, studying alternative
treatment in the case conventional treatment fails. Fi-
nally we would like to emphasize the importance of a
proper health education, daily ulcer care and shoe ad-
justments as systemic therapy and also to prevent the
development of new ulcers.
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